FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based cell therapies for degenerative diseases and other conditions. The company's core business activities are Shariah-compliant, focusing on healthcare innovation without involvement in prohibited sectors. Financial screening shows compliance with most ratio thresholds except AAOIFI's liquidity criterion. No index inclusion due to small market capitalization and liquidity constraints, leading to an overall non-compliant status. Purification is not required, and ESG factors align well with Islamic principles.